Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

About this update from Achieve Life Sciences, Inc.

[{"type":"image","alt":"Achieve Life Sciences","displaySize":"","headline":null,"caption":"Achieve Life Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/54cb79df5ae9ba9fc58a8a917402fc80"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UhVN6FI.pSC2XZoJQyyabQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54cb79df5ae9ba9fc58a8a917402fc80","width":300,"height":157}},"lazy":false},{"type":"text","content":"Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025","length":77,"tagName":"p"},{"type":"text","content":"Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025","length":75,"tagName":"p"},{"type":"text","content":"SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025.","length":515,"tagName":"p"},{"type":"text","content":"“The Achieve team is fully committed to finalizing the NDA for submission to the FDA next month. This pivotal milestone is the culmination of our team’s tireless efforts. It marks a critical inflection point as we move towards delivering the first new FDA-approved treatment for smoking cessation in nearly 20 years,” said Rick Stewart, Chief Executive Officer of Achieve. “Cytisinicline has the potential to have a significant benefit on U.S. public health with patients and their healthcare providers needing new options to improve cessation outcomes.”","length":554,"tagName":"p"},{"type":"text","content":"Recent Highlights ","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced publication of the second Phase 3 ORCA-3 trial results in the Journal of American Medical Association (JAMA) Internal Medicine that evaluated cytisinicline for smoking cessation in 792 U.S. adults","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Reached key requ...

More updates from Achieve Life Sciences, Inc.